SR-717

SR-717 is a potent, non-nucleotide small molecule agonist of the Stimulator of Interferon Genes (STING) protein. Developed by researchers at Scripps Research, it functions as a mimetic of the natural ligand cGAMP (cyclic GMP-AMP). SR-717 binds to the STING dimer and induces a conformational change into the active 'closed' state, which triggers the production of Type I interferons and other pro-inflammatory cytokines. Unlike many cyclic dinucleotide-based STING agonists, SR-717 is designed for improved stability and systemic bioavailability. In preclinical studies, it has demonstrated significant anti-tumor activity by enhancing the recruitment and activation of CD8+ T cells and natural killer (NK) cells within the tumor microenvironment. It is also utilized in research to study the role of the cGAS/STING pathway in inflammatory and degenerative diseases, such as osteoarthritis.